NCT05931328View on ClinicalTrials.gov

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2026

Conditions

Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

Interventions

DRUG

thiotepa combined with pomalidomide

thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Jiangsu Province People's Hospital., Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER